The phosphorylation of Drp1 was decreased after 24 h of treatment with liraglutide 10 nM in the PAH PASMCs, and these effects were blocked by the GLP-1R antagonist exendin (9–39) (Figure 5). The gene discussed is GLP1R; the disease is pulmonary arterial hypertension.